局灶不可逆电穿孔作为局限性放疗后复发前列腺癌挽救治疗的可行性与安全性
本研究评估局灶不可逆电穿孔(IRE)用于局限性放疗后复发前列腺癌的可行性、安全性、早期生活质量和肿瘤学结局。18例患者中位随访21个月,无CTCAE>2级不良事件或直肠尿道瘘,短期数据显示局灶IRE是可行的挽救选择,但需前瞻性多中心FIRE试验进一步验证。
要点
- 18例患者中位随访21个月,无高级别不良事件或直肠尿道瘘。
- 6个月时EPIC性功能域评分中位数由38降至24(P=0.028),排尿域由96降至92(P=0.074)。
- 8/10例随访活检无前列腺癌,2例为ISUP 5级显著前列腺癌。
核心结论
- 短期安全性、生活质量和肿瘤控制数据显示局灶IRE是局限性放疗后复发前列腺癌的可行挽救选择。
- 已启动前瞻性多中心FIRE试验,将进一步探究局灶IRE在可接受患者并发症前提下获得肿瘤控制的能力。
研究设计与样本
- 评估局灶IRE用于无转移或淋巴结证据的局限性放疗后复发前列腺癌患者,按共识指南提供治疗。
- 纳入随访至少6个月的患者进行分析,共18例,中位随访21个月。
主要发现
- 无CTCAE>2级高级别不良事件或直肠尿道瘘发生。
- 生活质量评估(n=11)中EPIC肠道域(P=0.29)、AUA症状评分(P=0.77)、SF-12躯体(P=0.17)和心理(P=0.77)均无统计学显著下降。
- 6个月时EPIC性功能域评分中位数由38降至24(P=0.028),排尿域由96降至92(P=0.074)。
- 6个月时8/11例保持无尿垫控尿,2/6例保持足以性交的勃起。
- mpMRI在11/13例中清晰,2例为单灶野外病变(分别为真阳性和假阳性)。
临床怎么用
- 作者认为局灶IRE是局限性放疗后复发前列腺癌的可行挽救选择。
- 作者指出已启动前瞻性多中心FIRE试验以进一步提供局灶IRE肿瘤控制能力的见解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the feasibility, safety, early quality-of-life (QoL) and oncological outcomes of salvage focal irreversible electroporation (IRE) for radio-recurrent prostate cancer (PCa). PATIENTS AND METHODS: Patients with localized, radio-recurrent PCa without evidence of metastatic or nodal disease were offered focal IRE according to the consensus guidelines. Patients with a minimum follow-up of 6 months were eligible for analysis. Adverse events were monitored using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0). Patient-reported QoL data were collected at baseline, 6 weeks, 3, 6 and 12 months using the Expanded Prostate Cancer Index Composite (EPIC), the American Urological Association (AUA) symptom score and the 12-item short-from health survey (SF-12) physical and mental component summary questionnaires. Oncological control was evaluated according to serial prostate-specific antigen (PSA), 6-month multiparametric magnetic resonance imaging (mpMRI) and 12-month prostate biopsy. Wilcoxon's signed rank test was used to assess QoL differences over time in paired continuous variables. RESULTS: A total of 18 patients were included in the analysis. The median follow-up was 21 months. No high-grade adverse events (CTCAE >2) or recto-urethral fistulae occurred. No statistically significant declines were observed in QoL outcomes (n = 11) on the EPIC bowel domain (P = 0.29), AUA symptom score (P = 0.77), or the SF-12 physical (P = 0.17) or SF-12 mental component summary (P = 0.77) questionnaires. At 6 months, patients who had undergone salvage therapy experienced a decline in EPIC sexual domain score (median of 38-24; P = 0.028) and urinary domain (median of 96-92; P = 0.074). Pad-free continence and erections sufficient for intercourse were preserved in 8/11 patients and 2/6 patients at 6 months, respectively. The mpMRI was clear in 11/13 patients, with two single out-field lesions (true-positive and false-positive, respectively). The median (interquartile range) nadir PSA was 0.39 (0.04-0.43) μg/L. Three and four patients experienced biochemical failure using the Phoenix and Stuttgart definitions of biochemical failure, respectively. Eight out of 10 of the patients were clear of any PCa on follow-up biopsy, whereas two patients had significant PCa on follow-up biopsy (International Society of Urological Pathology grade 5). CONCLUSION: Our short-term safety, QoL and oncological control data show that focal IRE is a feasible salvage option for localized radio-recurrent PCa. A prospective multicentre study (FIRE trial) has been initiated that will provide further insight into the ability of focal IRE to obtain oncological control of radio-recurrent PCa with acceptable patient morbidity.
引用
- Scheltema MJ, van den Bos W, Siriwardana AR, et al. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer. BJU Int. 2017. PMID: 28834167. doi:10.1111/bju.13991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。